New Press Releases 6 January 2012 CMP Therapeutics gains CE mark for Novel Rhinitis product - Atlantic Secret™. Download PDF Previous Press Releases 29 July 2010 CMP Therapeutics Ltd (CMPT) announces the appointment of Dr Neill Moray Mackenzie as CEO and the injection of a € 1.5 million convertible loan from Inventages Venture Capital. Download PDF 31 January 2006 CMP Therapeutics Ltd (CMPT) announces completion of € 4.5 million series A funding round to develop a treatment for respiratory allergies. Download PDF Scientific Publications Intranasal application of chitin microparticles down-regulates symptoms of allergic hypersensitivity to Dermatophagoides pteronyssinus and Aspergillus fumigatus in murine models of allergy. P. Strong, H.Clark, K.Reid. Clin Exp Allergy 2002; 32 : 1794n -1800 Download PDF Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant. Hideki Hasegawa, Takeshi Ichinohe, Peter Strong, Izumi Watanabe, Satoshi Ito, Shin-ichi Tamura, Hiehiro Takahashi, Hirofumi Sawa, Joe Chiba, Takeshi Kurata, Tetsutaro Sata. J. Medical Virology, 2005; 75, 130 - 136 Download PDF Treatment with chitin microparticles is protective against lung histopathology in a murine asthma model. C. Ozdemir, D. Yazi, M. Aydogan, T. Akkoc, N. N. Bahceciler, P. Strong , and I. B. Barlan Download PDF Prophylactic Effects of Chitin Microparticles on Highly Pathogenic H5N1 Influenza Virus Takeshi Ichinohe, Noriyo Nagata, Peter Strong, Shin-ichi Tamura, Hidehiro Takahashi, Ai Ninomiya, Masaki Imai, Takato Odagiri, Masato Tashiro, Hirofumi Sawa, Joe Chiba, Takeshi Kurata, Tetsutaro Sata, and Hideki Hasegawa Download PDF   To discuss partnership opportunities contact Dr Neill Moray Mackenzie